Abstract: Much remains to be learned about the structures, functions and therapeutic potentials of anion-permeable ion channels expressed throughout the nervous system. For example, the molecular identities of Ca 2+ -and swellingactivated Cl -channels are still unknown. Even in well-established neuronal anion channel families (the CLC and GABA type-A ion channel receptors), significant gaps exist in our understanding of the physiological functions and sub-cellular distributions of particular subtypes. The first part of this review summarises the current status of this field and discusses how the discovery of highly-selective pharmacological probes will advance our understanding of the molecular identities, cellular and sub-cellular distributions and functional roles of neuronal Cl -channels. Where relevant, the therapeutic potential of these channels is also discussed. The review then considers the relative merits of high-throughput methods that have been employed to screen anion-permeable channels. It concludes that several methods are potentially suited to screening homogeneous assays (such as stably-expressing cell lines), with the choice of method being governed largely by the detection equipment available. However, an anion-quenchable yellow fluorescent protein method is unique in that it retains full dynamic range in assays comprising transiently-transfected cells where the percentage of cells expressing recombinant channels is significantly < 100%. This feature is a significant advantage for screening the vast range of possible GABA type-A receptor subunit combinations where the creation of numerous stably-expressing cell lines would otherwise pose a substantial logistical challenge.
INTRODUCTION
The structures, distributions and functions of anionselective ion channels are generally less well-characterised than their cation-selective counterparts [38] . For example, the molecular identities of swelling-and Ca 2+ -activated Cl -channels are still unknown, and the Cl -channel status of at least 2 putative Cl -channel structural families (the CLCAs and CLICs) remains to be confirmed [38, 59] . There are also substantial deficiencies in our understanding of the roles of Cl -channel families of known structure. For example, little is known of the physiological functions and distributions of some voltage-gated Cl -channel (CLC) family members [37, 38] , or of the physiological rationale for the enormous diversity in subunit composition of the GABA A receptor Cl -channel (GABA A R) family [71, 75, 76, 93] . This review focuses Cl -channels expressed in neurons, because this is where the major deficiencies in our understanding lie. The only Cl -channel class that is not represented in the nervous system, the cystic fibrosis transmembrane regulator (CFTR), has a well-defined role and distribution [24, 38] . Moreover, high-throughput methods are well in-hand for screening this receptor [26, 74, 87, 97] .
A wide range of techniques for screening of Cl -channels is now in use, with several having been introduced in the last few years. Some of these assays, including high-throughput patch-clamp electrophysiology, radioactive assays and voltage-sensitive dyes (VSDs) are equally applicable to anion-and cation-selective channels. However, several other assays, including anion-sensitive yellow fluorescent proteins (YFPs) [27] , a pH-based method [77] and a colorimetric *Address correspondence to this author at School of Biomedical Sciences, University of Queensland, Brisbane, QLD 4072, Australia; Tel: +617 3365 3157; Fax: +617 3365 1766; E-mail: j.lynch@uq.edu.au assay employing the Sandell-Kolthoff reaction [84] are applicable only to anion-permeable channels. The purpose of this review is to highlight the deficiencies in our understanding of the molecular identity, distribution and function of neuronal Cl -channels, and to compare the potential of different high-throughput screening (HTS) methodologies for rectifying these deficiencies.
NEURONAL CL -CHANNEL FAMILIES

The CLC Cl -Channel Family
The vertebrate CLC family of voltage-gated Cl -channels comprises CLC0 to CLC7, plus CLCKa and CLCKb [38] . These channels generally function as homodimers, although some subunits are able to co-assemble as heterodimers in heterologous expression systems [50, 91] . The channels are 'double-barrelled', with each subunit containing an integral pore that can be gated individually or in conjunction with the pore in the companion subunit. The CLCK channels require the small accessory subunit, barttin, for functional expression [19] . Together, the CLC channels participate in a broad and expanding range of physiological functions. Hereditary mutations to human CLC or barttin genes underlie several disorders including myotonia congenita, Dent's disease, osteopetrosis, Barrter's syndrome and epilepsy [37, 38] .
Some CLC subunits do not appear to exist in the nervous system. For example, CLC0 has been found only in the Torpedo marmorata electric organ [39] , CLC1 is found only in muscle [79] , the CLCKs are restricted to the kidney and epithelial cells of the inner ear [19] , whereas CLC5 channels are found predominantly in the kidney [80] . The other members are all distributed widely throughout the body. Although it is likely that all are expressed in neurons, CLC2 is the only member that has unequivocally been identified in neuronal plasma membranes [13, 38, 78] . Human hereditary mutations that disrupt the expression of CLC2 are proposed to underlie a form of idiopathic generalised epilepsy [32, 58] . CLC2 transcripts or protein are found in pyramidal cells of hippocampus, cerebellar Purkinje cells, and in bipolar and pigment epithelial cells of the retina [38] . It is less abundant in other neurons and glia. There are no specific pharmacological markers for these channels, and to date, they can only be distinguished from other voltage-gated and Ca 2+ -activated Cl -channels by a rather imprecise set of functional criteria (e.g., iodide/chloride permeation sequence, voltage-dependence, potency sequence of blockers with weak specificities and low affinities). Nevertheless, such criteria have been used to convincingly establish the presence of CLC2 channels in neurons and glia [13, 60, 78] . As these channels are activated by hyperpolarisation, one role may be to shunt large excitatory GABA A -or glycinestimulated responses [78] . The development of selective antagonists would be invaluable in defining the distribution of CLC2 channels and for differentiating their roles from those of other Cl -channels in the same cells.
The remaining members, CLC3, CLC4, CLC6 and CLC7 have been localised primarily to the membranes of intracellular organelles [38] . As it is difficult to make direct electrophysiological recordings from such structures, biochemical and cell biology techniques have generally been used to characterise their distribution and physiological function. Genetically-modified mice have been particularly useful in this respect for CLCs 3 and 7 [37] . CLC3 is found in synaptic vesicles and in endosomal/lysosomal compartments, where it is necessary for vesicle acidification [81] . There is currently some uncertainty as to whether it is also expressed in the plasma membrane in vivo. Although CLC4 does express at the plasma membrane in heterologous expression systems [21] , little is known about its physiological role. The role of CLC6 is also unknown. CLC7 is localised to late endosomes and lysosomes and is strongly expressed in neurons. Disruption of this gene in mice leads to a lysosomal storage disorder, osteopetrosis and severe retinal neurodegeneration [46] . Specific pharmacological probes with high specificity for vesicular CLC channels would be extremely useful for establishing their functions. However, the efficient search for such compounds would require the development of novel high-throughput screening assays for intracellular ion channels.
The Cysteine-Loop Cl
-Channel Family
GABA A R
The GABA A R is a member of the nicotinic acetylcholine receptor family of ligand-gated ion channels. Receptors of this class comprise 5 subunits arranged symmetrically around a central ion-conducting pore. Each subunit comprises 4 -helical TM domains and a large extracellular amino-terminal domain that harbours the ligand binding sites and the signature 'cysteine-loop'. GABA A Rs mediate inhibitory neurotransmission in most parts of the central nervous system. They are constructed from a family of around 16 different subunits ( 1 6, 1 3, 1 3 , , , , ) plus a few splice variants. The 3 known GABA C R subunits (see below) may also co-assemble with GABA A R subunits [56, 63] . If all subunits were able to recombine randomly, they would produce an enormous number of receptors (> 100,000), each with a distinct electrophysiological and pharmacological profile [71, 76, 89] . Fortunately, however, the range of stoichiometries found in vivo is restricted [75, 92, 93] . Nevertheless, there remains a significant variability in the subunit composition of GABA A Rs found at CNS synapses and it remains a major challenge to establish which subunit combinations are expressed at a particular GABAergic synapse and why. Similarly, little is known about roles and subunit compositions of extra-synaptic GABA A Rs [62] . One way of identifying the subunit composition and physiological role of a particular ion channel subtype is to use highly specific blockers to eliminate their contribution to the complex suite of conductances active at any one time in a neuron. However, currently available pharmacological tools are generally not sufficiently selective to achieve this in the GABA A R. The current rate of progress towards the understanding of GABA A R diversity would be drastically enhanced by the identification of such subunit-specific antagonists. However, it is important to acknowledge that much of our current understanding of the roles of particular GABA A R subunits has come from studies that used potentiating agents as pharmacological probes [71, 72] .
GABA A Rs have long been important clinical targets for therapies directed at muscle relaxation, epilepsy, anxiolysis, sedation and anaesthesia. Novel therapeutic possibilities continue to emerge and these receptors are currently considered targets for indications including depression, drug addiction, psychosis, cognitive impairment and sleep disorders in the elderly [34, 49, 92] . However, there is considerable scope for the development of new therapeutics with improved beneficial effects and a reduced propensity for dependency and other side-effects. The search for novel GABA A R therapeutics is focussed on small molecule activators and allosteric potentiators.
GABA C R
GABA C Rs comprise homomers or heteromers of 1, 2 and 3 subunits, although they may also be able to coassemble with GABA A R or GlyR subunits [56, 63] . GABA C Rs are found mainly in the spinal cord, retina, superior colliculus, pituitary gland and gut [100] . Drugs acting at these receptors may be relevant to the treatment of sleep, visual and cognitive disorders [40] . GABA C Rs are distinguished from GABA A Rs by robust pharmacological criteria [100] . While current tools are sufficiently sensitive to differentiate GABA C -from GABA A -mediated currents, they are not sufficiently sensitive to identify the presence of particular GABA C R subunits in homomeric or heteromeric receptors.
GlyR
GlyRs are best known for mediating inhibitory synaptic transmission onto motor and sensory neurons in the spinal cord. Glycinergic synapses are also present in the retina and brainstem [52] . Non-synaptic GlyRs are found throughout the central nervous system as well as in sperm [55] , macrophages and leucocytes [33] . A total of 5 GlyR subunits ( 1-4 and ) have been identified to date. Embryonic receptors comprise 2 homomers, whereas adult receptors comprise predominantly 1 heteromers in a 2:3 stoichiometry [30] . Notably, the 3 subunit is present in GlyRs that mediate inhibitory neurotransmission onto spinal nociceptive neurons. The activity of this subunit is downregulated by inflammatory mediators, implying a role in neuropathic pain [3, 31] . GlyRs are emerging as promising targets for muscle relaxant and peripheral analgesic drugs. GlyRs are potently and specifically antagonized by nanomolar concentrations of strychnine. In addition, several drugs are effective in identifying the presence of certain subunits in heteromeric GlyRs [52] . Thus, the need for high affinity, high-specificity antagonists is not as high for the GlyR as it is for other neuronal Cl -channels.
Invertebrate Ligand-Gated Anion Channels
Several invertebrate-specific ligand-gated Cl -channels have been identified in the genetic model organisms, C. elegans or D. melanogaster. These include channels gated by histamine [28] , serotonin [69] and glutamate [14] . Putative acetylcholine-gated anion channel subunit transcripts have also been identified in C. elegans [57] , although these have yet to be functionally expressed. As C. elegans in particular, is an important model of nervous system function, it would undoubtedly be useful to identify highly specific antagonists for these receptors for use in functional assays. However, these Cl -channels are also important targets for anti-parasitic drugs, and there is considerable scope for using these channels as targets for the next generation of therapeutics to control nematode and insect parasites [70] .
Other Neuronal Cl -Channels with Known Molecular Identity
Transporters
Cl -transporters and ion channels have similar roles in translocating Cl -ions across cell membranes. Generally, transporters have lower flux rates than channels, as the transport of (usually) a single ion requires an entire conformational 'activity cycle'. In contrast, a single ion channel opening event will typically result in the flux of 1000s of ions, with the direction of flux being determined by the Nernst equation. This higher flux rate means that channels are more amenable to HTS than transporters. In addition, Cl -transporters frequently flux other substrates and it may be these substrates that are monitored by HTS methods. Because this review focuses on methods of assaying Cl -flux, its scope is limited to those transporters that incorporate Nernstian Cl --selective pores.
Excitatory amino acid transporters (EAATs) in the brain control the extracellular concentration of synapticallyreleased glutamate. The inward transport of glutamate requires co-transport by three Na + and one H + , coupled to the counter-transport of one K + [99] . Glutamate and Na + also gate a Cl --conducting ion channel pore that is intrinsic to the transporter protein [20] . A total of 5 EAAT family members have been identified (EAATs1-5). EAAT1 and EAAT2 are found on glial cell membranes near to glutamatergic synapses [11] . EAAT3 and EAAT4 are generally found in the peri synaptic region of neuronal membranes, with EAAT3 being broadly distributed throughout the CNS, and EAAT4 being expressed exclusively in cerebellar Purkinje cells [15, 17, 96] . EAAT5 expression is largely restricted to the retina [6] . EAATs 4 and 5 appear to possess much greater Cl -flux rates than the other members of this family [5] . Although the role of these proteins in controlling extracellular glutamate is abundantly clear, the role of the Cl -conductance is mostly a matter of conjecture. One hypothesis is that it acts to counterbalance the depolarisation associated with electrogenic glutamate uptake that might otherwise cause a reduction in transport rate [18] . In photoreceptors, where EAAT5 is found pre synaptically, the Cl -current may serve a negative feedback role on membrane depolarisation to limit the release of glutamate [5] . Apart from kainite and dihydrokainate, which exhibit a high specificity for EAAT2 relative to the other family members [7, 35] , there are few specific blockers for these proteins. Obviously, subunitspecific blockers would be of great assistance in identifying the role of the EAAT Cl -conductance, and in differentiating between the roles of EAAT isoforms.
Bestrophins
Hereditary mutations to bestrophins underlie a human retinal disorder, Best vitelliform macular degeneration [53, 64] . A total of 4 bestrophin subunits (Best1-4) have been identified. Their distribution appears to be wide spread, although with the exception of the retina [9] , it has not been mapped in detail. Their subunit stoichiometry is not known. Hydropathy analysis predicted Best to form a transmembrane protein, and it was duly shown that recombinant expression in a mammalian cell line resulted in the appearance of a Ca 2+ -activated Cl -conductance [68, 83] . However, for a time, it was unclear whether Best formed a Cl -channel itself or whether it promoted the expression of another Cl --conducting protein. It has now been demonstrated by the use of permeation-altering mutations that Best2 is indeed a Ca 2+ -activated Cl -channel [67] . Unfortunately, since the physiological and pharmacological properties of bestrophins do not show much deviation from generic Cl -channel properties [66] , it is not straightforward to assign physiological roles to this channel. There is little doubt that highly specific pharmacological markers would be helpful in defining the distribution and function of this channel.
Putative Neuronal Cl -Channels
For reasons that have been reviewed in detail elsewhere [38, 59] , the CLCA family of putative Ca 2+ -activated Cl -channels and the CLIC family of putative intracellular Cl -channels are best regarded as Cl -channel candidates. They are noted briefly here because there is evidence that members of both families are expressed in the brain [2, 82] .
Neuronal Cl -Channels of Unknown Molecular Identity
Ca
2+ -Activated Cl -Channels
The extensive literature on Ca 2+ -activated Cl -channels of native tissues has been the subject of an excellent review by Frings and colleagues [22] . In the nervous system, the role of these channels has been most thoroughly characterised in olfactory sensory neurons. A Ca 2+ -activated Cl -channel was first identified in olfactory sensory cilia by Kleene and Gesteland [45] . Odorant detection in these cells is mediated by odorant-sensitive G-protein coupled receptors. When stimulated, these receptors induce a rapid increase in cAMP, which in turn directly activates a Ca 2+ -permeable cyclic nucleotide-gated cation channel [23] . Ca 2+ influx through this channel activates a depolarising Cl -current that greatly amplifies the transduction signal [44, 48, 51] . The Cl -current is depolarising due to the unusually high (40-50 mM) intracellular Cl -concentration [42] . Ca 2+ -activated Cl -channels are also present in subsets of dorsal root ganglion neurons [54] , spinal cord neurons [61] and sympathetic ganglion neurons [4] . The specific roles of the currents in these neuronal types are not understood. Ca 2+ -activated Cl -currents have also been identified in photoreceptors [8] , where it is hypothesised they are involved in either surround antagonism (i.e., inhibition by an illuminated photoreceptor of neighbouring photoreceptors) or stabilisation of the resting potential [22] . As with most other neuronal Cl -channel classes, the sensitivity and specificity of currently available pharmacological probes is poor [22] .
Swelling-Activated Cl -Channels
Swelling-activated Cl -channels are activated by a reduction in extracellular osmolarity or an increase in intracellular osmolarity. An indanone derivative, DCPIP, selectively blocks an endothelial cell swelling-activated Cl -channel with a potency in the low micromolar range [16] . The channels are expressed ubiquitously. Although several proteins have been proposed as candidates for this conductance, its molecular identity remains unknown [59, 73] . Because cell volume regulation is paramount for cell survival, gene deletion approaches are likely to produce lethal phenotypes, and expression cloning approaches are likely to be complicated by endogenous swelling-activated Cl -currents [73] . The development of high-affinity specific blockers appears to offer one of the few avenues for identifying and purifying this elusive channel species.
Conclusion So Far
There are three distinct reasons for screening neuronal Cl -channels. The first is to identify ligands with high affinity and high specificity for use in the purification and biochemical characterisation of Cl -channel proteins. This will aid not only in the molecular identification of channels that are currently identifiable only by their function in native tissues (i.e., Ca 2+ -activated and swelling-activated Cl -channels), but may also help map the distribution of those channels of known molecular identity for which questions remain concerning their tissue or sub-cellular distributions (e.g., bestrophins, some CLCs).
The second reason is to identify antagonists with high specificity for particular Cl -channel subunits or subunit combinations. Selective antagonism is the simplest means of assessing the contribution of a particular ion channel to neuronal function, as it deletes the current of interest from the complex background of ion channel activity. Agonists and allosteric potentiators are less useful in this respect, because they may activate the channel to unrealistic levels, thereby providing little information about its physiological role. In addition to providing information about channel function, specific antagonists can also provide information about their subunit composition. Specific antagonists could even be used to establish whether putative Cl -channels (e.g., CLCAs, CLICs) do indeed possess an intrinsic Cl --conducting pore. The venoms of poisonous creatures, such as cone snails, spiders, scorpions and snakes, comprise complex cocktails of peptides with exquisite sensitivity and specificity for particular ion channel types. Such peptides have proved invaluable in characterising the subunit compositions and physiological roles of many cation-selective ion channel subtypes (e.g., [85] ). Surprisingly, no peptide toxin ligand has yet been identified for any neuronal Cl --selective channel.
The third reason for screening neuronal Cl -channels is to identify novel clinical lead compounds. The GABA A R is currently the only neuronal Cl -channel that is an important therapeutic target. However, as more becomes known about the roles of other Cl -channel types, novel therapeutic possibilities are certain to emerge.
HTS TECHNIQUES
Automated Patch-Clamp Electrophysiology
Patch-clamping is the definitive means of assaying ion channel function. It not only offers an unrivalled signal-tonoise ratio but also tracks the effects of compounds in real time. The later feature offers two unique advantages. First, it permits complex effects of compounds to be resolved. For example, a compound that elicits a transient potentiation of current followed by a sustained inhibition can readily be identified. Second, it permits the direct kinetic analysis of compound binding and unbinding rates (as well as the voltage-dependence of such rates), which can often provide information about the site and mechanisms of action of compounds. For these reasons, patch-clamping is considered the 'gold standard' for ion channel screening. It is not surprising that several companies are engaged in developing automated whole-cell patch-clamp technologies [41, 90, 94, 101] . At this stage, the consensus is that the applicability of this technology is limited by its high cost and modest throughput [41, 90, 94, 101] . Standard low-throughput patchclamping is already indispensable to the ion channel screening process, because it is the definitive means of confirming the activity of compounds identified by other assays.
Radioactive Assays
These can be separated into radioligand displacement assays and radiotracer flux assays. Radioligand displacement assays incorporate the use of a relatively high-affinity ligand that is labelled with a radioactive tracer. Commonly-used examples include 3 H-strychnine to label the GlyR [98] and the benzodiazepine ligands, 3 H-flunitrazepam and 3 H-Ro15-1788, to label the GABA A R [65] . These assays involve displacing the radiolabel with unlabelled test compound. There are several limitations to this technology. First, it provides no information about the effect of the compound. That is, it is not possible to distinguish whether a compound behaves as an agonist or an antagonist, or indeed, whether it has no effect at all. (Note, however, that functionality may be of secondary importance when screening for high affinity compounds to use in the detection and purification of particular channel subtypes.) Another limitation is that it does not detect compounds that bind to and modify the receptor without displacing the radioligand. Furthermore, long incubations with radiolabelled agonists may promote a desensitised state with different pharmacology to the normal resting closed or activated states [10] . The technique is also limited to those channels for which high affinity and high specificity ligands are available. As discussed above, such ligands do not exist for some types of neuronal Cl -channels.
Radioactive tracer flux assays detect the transmembrane flux of the radioactive anions, 125 I -or 36 Cl - [43, 86] . Note that I -is highly permeant through most, but not all, Cl -channels. Being an assay of receptor function, this technique overcomes some of the limitations of radioligand displacement assays.
In general, radioactive assays have not attained wide popularity in the high-throughput industry primarily because of the need for long incubation times and multiple processes (e.g., tracer loading, cell-wash and cell lysis steps) that limit high throughput, the high cost of materials, and the inconvenience and risk associated with the handling and disposal of radioactive materials. Signal-to-noise ratio will be reduced in heterogeneous assays (i.e., those assays that comprise multiple cell types and/or multiple Cl -channel types).
Colorimetry
This method, first applied to Cl -channel screening by Tang and Wildey [84] , detects transmembrane iodide flux via the Sandell-Kolthoff reaction: --containing buffer. The channels are activated allowing I -to flow into the cell down its electrochemical gradient. The rate of accumulation of intracellular I -will depend on the degree to which the channels are activated. Following the experiment, cells are lysed and the lysate is placed in a detection buffer containing equi molar amounts of Ca 4+ and As 3+ . Since the rate of the above reaction is I --dependent, the colour of the detection buffer after a given period of time provides an indication of the transmembrane I -flux rate. As with tracer flux assays, this method also works in reverse (Fig. 1) . That is, cells can be pre-loaded with I -and the rate of extracellular I -accumulation can be quantitated in the same way. Because the reaction will eventually proceed to the same steady-state regardless of the I -concentration, it is necessary to control the length of time that the reaction is allowed to proceed. This requirement for precise timing may constitute a limitation of this approach. The originators of this technique minimised systematic errors due to nonsynchronised detection by setting their plate reader to the highest possible scan speed [84] . This assay has the advantage of low cost. It also avoids the safety and environmental issues associated with use and disposal of radioactive materials. However, as with the radioactive tracer flux assay, its utility is limited by the requirement for tracer loading, cell wash and/or lysis steps. Its signal-to-noise ratio will also be reduced in heterogeneous assays.
pH
Most Cl -channels are highly permeant to HCO 3 -ions. As this ion exists at a high concentration inside cells, it diffuses out of the cell as Cl -channels are opened, leading to an increased intracellular pH [12] . However, Simpson and colleagues [77] found that when the extracellular buffer was acidified to pH 6.9, the activation of GABA A Rs caused a small transient increase and then a sustained reduction in intracellular pH. This pH change, which was measured by changes in the fluorescence of the pH-sensitive dye, 2',7'bis-(2-carboxyethyl)-5-(and 6)-carboxyfluorescein (or BCECF), appeared to have been mediated by the activity of multiple transporters stimulated by the initial GABA-evoked pH increase (Fig. 1) . This assay was shown to provide a robust indication of the activation of GABA A Rs stably expressed in L(tk-) cells [77] . However, as shown in Fig. 2 , the responses were slow (1 -2 min) to reach steady-state, and the percentage changes in fluorescence were small (< 5 %). These characteristics may limit the utility of this technique depending on the flexibility and sensitivity of the detection equipment. The response characteristics are likely to vary between cell types due to differences in the complement and relative activities of endogenous ion transport mechanisms. This assay may produce false (positive or negative) indications by compounds affecting other ion transport mechanisms.
As a general point, the use of exogenous dyes has other limitations. First, they constitute a significant recurrent expense and second, they require dye loading and cell-wash steps that limit high throughput. Third, and perhaps most seriously, exogenous fluorescent dyes are taken up by all cells regardless of whether or not they express the Cl -ion channel of interest. If, for example, only half the cells express the ion channel of interest, then the dynamic range of the net fluorescence response is halved. Thus, to achieve its full dynamic range, all cells must respond to the dye. This requirement means that techniques involving exogenously applied indicators are suited primarily to homogeneous assays such as cell lines that stably express the Cl -channel of interest.
VSDs
A wide range of VSDs is commercially available. VSD selection often involves a trade-off between speed of response and dynamic range. In HTS applications, dynamic range is the first consideration. The FLIPR ® fluorescent membrane potential (FMP) dye marketed by Molecular Devices is currently the dye of choice for HTS [95] . It has long been popular for screening cation-selective channels and has recently been investigated in HEK293 cells stably expressing the GlyR 1 subunit [36] or EAAT1-3 subunits [35] . In the case of the GlyR, the assay was set up so that Cl -channel activation induced a depolarisation and a consequent increase in fluorescence (Fig. 1) . However, the EAAT assay measured a voltage change that was the net result of the translocation of several ions transported by these proteins [35] . In both studies [35, 36] , the response of the dye was relatively slow, taking at least 30 s to reach steady-state (Fig.  2 A ) . VSDs suffer from the same limitations as any exogenously-applied indicator (see above). Nevertheless, the high quantum efficiency and dynamic range of FMP largely compensate for these.
High response speed and dynamic range can be achieved simultaneously using fluorescence resonance energy transfer (FRET). This technique involves the non-radiative transfer of energy from a donor fluorophore to an acceptor fluorophore provided, 1) the donor emission spectra and acceptor absorption spectra overlap and, 2) they are in close proximity (20-100 Å) (Fig. 1) . When the donor is excited at its absorption wavelength, FRET causes the acceptor fluorescence to increase and donor fluorescence to decrease. It has been shown that the donor, CC2-DMPE, and the acceptor, DiBac2, produce a robust FRET at negative membrane potentials when both lie at the external membrane surface [29] . Upon depolarisation, DiBac2 crosses the membrane, thereby increasing its distance from CC2-CPMPE and decreasing FRET efficiency (Fig. 1) . The voltage-induced fluorescence change occurs rapidly over a large dynamic range [29] . This method has been used to screen GABA A Rs [1] . In these experiments, cells were bathed in low-Cl -buffer so that GABA A R activation induced Cl -efflux, leading to depolarisation (Fig. 1) . This technique provides a rapid and sensitive indication of GABA A R activation (Fig. 2) . However, the technique is expensive, as it requires 2 exogenous fluorescent indicators. Also, because the plasma membrane concentrations of the respective fluorophores must be optimised individually for maximum FRET efficiency [29] , this technique requires two dye incubation and wash steps. As with other assays incorporating exogenously-applied dyes, it is suited primarily to homogeneous assays. 
YFP
YFP, an engineered variant of green fluorescent protein, is quenched by small anions and is thus suited to reporting anionic influx into cells [88] (Fig. 1) . A random mutagenesis approach identified 2 mutations, I152L and V163S, each of which greatly enhanced YFP anion sensitivity [25] . The I152L mutation confers a particularly high sensitivity to I -quench (K i ~ 3 mM). YFP-I152L has proved useful in HTP screening of the anion-conducting cystic fibrosis transmembrane regulator [27, 97] . It has recently been applied to the GlyR and GABA A R by Kruger and colleagues [47] . This assay has 3 distinct advantages over the FMP VSD assay. First, although both assays have similar signal-to-noise ratios and dynamic ranges, the YFP assay is faster by a factor of at least three in achieving a given percentage fluorescence change (Fig. 2) . Second, as a propagable substance, YFP cDNA is cheaper. (On the other hand, however, the additional expense of transfection reagents may be incurred if YFP is transiently transfected into cells.) The third advantage stems from the fact that VSDs are incorporated into all cells. As discussed above, this means that homogeneous assays (e.g., stably expressing cell lines) are essential for optimal VSD responses. In contrast, it has been shown that simultaneously transfecting YFP and ion channel subunits result in an extremely high rate of transient coexpression of YFP and functional recombinant channels, even without using a bi-cistronic vector [47] . Thus, the YFPbased assay does not require stably expressing cell lines to achieve its full dynamic range. This is a distinct advantage in screening the large number of possible GABA A R isoforms as it obviates need to create stably expressing cell lines of all desired subunit combinations. Finally, as a geneticallyencoded probe, YFP would also be suited to screening heterogeneous populations of isolated neurons where the YFP is transgenically expressed in a defined subset of neurons. If an imaging-based detection system is used, this assay would also be suitable for 'high-content' screening (i.e., the correlation of multiple variables in the same cell). CONCLUSION Many gaps remain in our understanding of the cellular and sub-cellular distributions, molecular identities, physiological roles and pharmacological profiles of neuronal Cl The panel labelled 'pH method' was reproduced from [77] with permission. The experiment was performed as shown in Fig. 1 . L(-tk) cells stably expressing the 5 3 2 GABA A R were loaded with BCECF and stimulated with 3 μM GABA either alone (middle trace), together with the benzodiazepine agonist chlordiazepoxide (upper trace) or with the benzodiazepine inverse agonist, 6,7-dimethyl-4-ethylcarboline-3-carboxylate (bottom trace). The panel labelled 'YFP' was reproduced from [47] with permission. HEK293 cells were transiently transfected with the GlyR 1 subunit and YFP-I152L. The experiment was performed as shown in Fig. 1 and the indicated concentrations of glycine were applied at time t = 0. channel types. This review has described how the development of specific pharmacological probes will expedite this process. Furthermore, there is already a great deal of interest in screening GABA A Rs for novel therapeutic lead compounds. Eventually, as the physiological roles of other Cl -channel types become better characterised, novel therapeutic possibilities will surely emerge. Thus, there is abundant scope for applying HTS to neuronal Cl -channels.
The choice of screening strategy depends on the assay type. Assuming the transfection rate is significantly < 100 %, cells transiently transfected with the Cl -channel are of interest and are best screened using YFP. This is because there is a high correlation between cells expressing YFP and those expressing the channel of interest. This approach is particularly suited to the screening of recombinant GABA A Rs as the creation of cell lines stably expressing a sufficient range of subunit combinations to establish compound specificity would present a considerable logistical challenge. However, YFP is not necessarily the method of choice for screening homogeneous assays. Detection systems based on colorimetry, pH, VSDs and YFP all have advantages and disadvantages, and the choice of a particular method will depend largely on the detection equipment available. For example, a slowly responding probe may be suited to high-throughput if multiple wells can be monitored simultaneously, but not if the wells must be monitored sequentially. 
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